Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2020-12-28 Director's Dealing
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
Director's Dealing 2020
Director's Dealing
2020-12-28 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content details the entry into a material definitive agreement, specifically an exclusive license agreement with The Cleveland Clinic Foundation. It includes detailed terms of the agreement, payment obligations, rights, and responsibilities. This type of filing is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing to disclose a significant corporate event. The document length is 8883 characters, which is substantial and contains the full text of the agreement announcement, not just a brief notice or a certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-12-01 English
Director's Dealing 2020
Director's Dealing
2020-11-03 English
Investor Presentation 2020
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 16, 2020, by Anixa Biosciences, Inc. The key content is the disclosure of a presentation given at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference, attached as Exhibit 99.1. The document explicitly states that the presentation is attached and may be used in future investor meetings. The length of the document is 3581 characters, which is relatively short and consistent with an announcement rather than a full report. The primary purpose is to disclose the presentation material used at a conference, which aligns with the definition of an Investor Presentation (IP). Therefore, the document should be classified as an Investor Presentation (IP).
2020-09-16 English
Director's Dealing 2020
Director's Dealing
2020-09-14 English
Director's Dealing 2020
Director's Dealing
2020-09-11 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.